Cronos Group (Cronos Group) Cash, Cash Equivalents, Marketable Securities : $861.53 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Cronos Group Cash, Cash Equivalents, Marketable Securities?

Cronos Group's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($840.94 Mil) to Sep. 2023 ($839.56 Mil) but then increased from Sep. 2023 ($839.56 Mil) to Dec. 2023 ($861.53 Mil).

Cronos Group's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($1,004.66 Mil) to Dec. 2022 ($877.72 Mil) and declined from Dec. 2022 ($877.72 Mil) to Dec. 2023 ($861.53 Mil).

Cronos Group Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Cronos Group's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cronos Group Cash, Cash Equivalents, Marketable Securities Chart

Cronos Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

1,506.04

1,289.79

1,004.66

877.72

861.53

Cronos Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															877.72	836.43	840.94	839.56	861.53

Cronos Group Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Cronos Group (NAS:CRON) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Cronos Group Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Cronos Group's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cronos Group (Cronos Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

7CI:Germany CRON:Canada

Address

111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1

Website

https://www.thecronosgroup.com

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.

Executives

Kamran Khan	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Elizabeth Seegar	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Dominik Meier	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Jason Marc Adler	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2G9
Mcginness James Andrew Iii	officer: VP, Controller	C/O MARKETWISE, 1125 N. CHARLES STREET, BALTIMORE MD 21201
Maple Holdco (bermuda) Ltd.	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Maple Acquireco (canada) Ulc	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Summit Llc	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Group, Inc.	10 percent owner	6601 WEST BROAD STREET, RICHMOND VA 23230
James Holm	officer: Chief Financial Officer	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Arye Weigensberg	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 MV5 2H1
Doucet Terrence Gregory Joseph	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
John Griese	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Ran Gorelik	officer: General Manager (Israel)	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Robert L Madore	officer: Chief Financial Officer	C/O RALPH LAUREN CORPORATION, 650 MADISON AVENUE, NEW YORK NY 10022